immunoglobulin; monoclonal antibody; against human mesenchymal stem cells
Permits/Forms:
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimay responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Tumorigenic:
Yes
Comments:
Animals were immunized with human mesenchymal stem cells. Spleen cells were fused with Sp2/0-Ag14 mouse myeloma cells. The antibody reacts with mesenchymal stem cells from bone marrow and some tissues of mesenchymal origin.
Propagation:
ATCC complete growth medium: The base medium for this cell line is ATCC Hybri-Care Medium, Catalog No. 46-X. Hybri-Care Medium is supplied as a powder and should be reconstituted in 1 L cell-culture-grade water. To make the complete growth medium, add the following components to the base medium:
fetal bovine serum to a final concentration of 20%
1.5 g/L sodium bicarbonate for use with 5% CO2 in air atmosphere ATCC tested fetal bovine serum is available as ATCC Catalog No. 30-2020. Temperature: 37.0°C
Subculturing:
Protocol: Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 2 X 10 exp5 and 1 X 10 exp6 cells/ml. Medium Renewal: Every 2 to 3 days
recommended serum:ATCC 30-2020 Recommended medium （without the additional supplements or serum described under ATCC Medium）:ATCC 46-X
References:
22086: Caplan AI, Haynesworth SE. Human mesenchymal stem cells. US Patent 5,486,359 dated Jan 23 1996 49752: Haynesworth SE, et al. Cell surface antigens on human marrow-derived mesenchymal cells are detected by monoclonal antibodies. Bone 13: 69-80, 1992. PubMed: 1316137
會(huì)員.png)
15
